{"id":"dutogliptin-filgrastim","safety":{"commonSideEffects":[{"rate":null,"effect":"Bone pain"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hypoglycemia"}]},"_chembl":{"chemblId":"CHEMBL1201567","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dutogliptin is a DPP-4 inhibitor that increases levels of active GLP-1 and GIP, enhancing insulin secretion and reducing glucagon in a glucose-dependent manner. Filgrastim is a recombinant G-CSF that mobilizes hematopoietic stem cells and promotes their differentiation, potentially supporting cardiac tissue repair and regeneration in the context of heart failure or myocardial injury.","oneSentence":"Dutogliptin inhibits dipeptidyl peptidase-4 (DPP-4) to enhance incretin signaling and improve glycemic control, while filgrastim stimulates granulocyte colony-stimulating factor (G-CSF) receptors to promote bone marrow recovery and cardiac regeneration.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:10:15.784Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Heart failure with reduced ejection fraction (HFrEF) with glycemic control"},{"name":"Post-myocardial infarction cardiac dysfunction"}]},"trialDetails":[{"nctId":"NCT05881382","phase":"PHASE3","title":"Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction","status":"UNKNOWN","sponsor":"Recardio, Inc.","startDate":"2023-09","conditions":"ST Elevation Myocardial Infarction","enrollment":4100},{"nctId":"NCT03486080","phase":"PHASE2","title":"Study of Dutogliptin in Combination With Filgrastim in Post-Myocardial Infarction","status":"COMPLETED","sponsor":"Recardio, Inc.","startDate":"2018-12-07","conditions":"Acute Myocardial Infarction, Acute Myocardial Ischemia, STEMI - ST Elevation Myocardial Infarction","enrollment":49}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Dutogliptin + Filgrastim","genericName":"Dutogliptin + Filgrastim","companyName":"Recardio, Inc.","companyId":"recardio-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dutogliptin inhibits dipeptidyl peptidase-4 (DPP-4) to enhance incretin signaling and improve glycemic control, while filgrastim stimulates granulocyte colony-stimulating factor (G-CSF) receptors to promote bone marrow recovery and cardiac regeneration. Used for Heart failure with reduced ejection fraction (HFrEF) with glycemic control, Post-myocardial infarction cardiac dysfunction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}